|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ganesh K and Massagué J: Targeting
metastatic cancer. Nat Med. 27:34–44. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yin W, Wang J, Jiang L and James Kang Y:
Cancer and stem cells. Exp Biol Med (Maywood). 246:1791–1801.
2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Olivares-Urbano MA, Griñán-Lisón C,
Marchal JA and Núñez MI: CSC radioresistance: A therapeutic
challenge to improve radiotherapy effectiveness in cancer. Cancers
(Basel). 9(1651)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shimura T, Nara H, Yamazaki M, Sasatani M
and Ushiyama A: Suppression of cancer stem-like cell
radioresistance by inhibiting AMPK signaling. J Radiat Res.
66:227–233. 2025.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yuan SF, Wang YM, Chan LP, Hung AC, Nguyen
HDH, Chen YK, Hu SC, Lo S and Wang YY: IL-1RA promotes oral
squamous cell carcinoma malignancy through mitochondrial
metabolism-mediated EGFR/JNK/SOX2 pathway. J Transl Med.
21(473)2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hasegawa K, Saga R, Takahashi R, Fukui R,
Chiba M, Okumura K, Tsuruga E and Hosokawa Y: 4-Methylumbelliferone
inhibits clonogenic potency by suppressing high molecular
weight-hyaluronan in fibrosarcoma cells. Oncol Lett. 19:2801–2808.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Oyama T, Hosokawa Y, Abe K, Hasegawa K,
Fukui R, Aoki M and Kobayashi W: Prognostic value of quantitative
FDG-PET in the prediction of survival and local recurrence for
patients with advanced oral cancer treated with superselective
intra-arterial chemoradiotherapy. Oncol Lett. 19:3775–3780.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fuchs D, Heinold A, Opelz G, Daniel V and
Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis
resistance in human cancer cells. Biochem Biophys Res Commun.
390:743–749. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Qi D, Liu Y, Li J, Huang JH, Hu X and Wu
E: Salinomycin as a potent anticancer stem cell agent: State of the
art and future directions. Med Res Rev. 42:1037–1063.
2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kuwahara Y, Mori M, Kitahara S and
Fukumoto M, Ezaki T, Mori S, Echigo S, Ohkubo Y and Fukumoto M:
Targeting of tumor endothelial cells combining 2 Gy/day of X-ray
with everolimus is the effective modality for overcoming clinically
relevant radioresistant tumors. Cancer Med. 3:310–321.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Begg AC, Stewart FA and Vens C: Strategies
to improve radiotherapy with targeted drugs. Nat Rev Cancer.
11:239–253. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Fukui R, Saga R, Matsuya Y, Tomita K,
Kuwahara Y, Ohuchi K, Sato T, Okumura K, Date H, Fukumoto M and
Hosokawa Y: Tumor radioresistance caused by radiation-induced
changes of stem-like cell content and sub-lethal damage repair
capability. Sci Rep. 12(1056)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Todoroki K, Ogasawara S, Akiba J, Nakayama
M, Naito Y, Seki N, Kusukawa J and Yano H: CD44v3+/CD24- cells
possess cancer stem cell-like properties in human oral squamous
cell carcinoma. Int J Oncol. 48:99–109. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Panagiotou E, Syrigos NK, Charpidou A,
Kotteas E and Vathiotis IA: CD24: A novel target for cancer
immunotherapy. J Pers Med. 12(1235)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Blick T, Hugo H, Widodo E, Waltham M,
Pinto C, Mani SA, Weinberg RA, Neve RM, Lenburg ME and Thompson EW:
Epithelial mesenchymal transition traits in human breast cancer
cell lines parallel the CD44(hi)/CD24(lo/-) stem cell phenotype in
human breast cancer. J Mammary Gland Biol Neoplasia. 15:235–252.
2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kawano T, Yanoma S, Nakamura Y, Ozeki A,
Kokatsu T, Kubota A, Furukawa M and Tsukuda M: Soluble CD44
standard, CD44 variant 5 and CD44 variant 6 and their relation to
staging in head and neck cancer. Acta Otolaryngol. 125:392–397.
2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Joshua B, Kaplan MJ, Doweck I, Pai R,
Weissman IL, Prince ME and Ailles LE: Frequency of cells expressing
CD44, a head and neck cancer stem cell marker: Correlation with
tumor aggressiveness. Head Neck. 34:42–49. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Davis SJ, Divi V, Owen JH, Bradford CR,
Carey TE, Papagerakis S and Prince ME: Metastatic potential of
cancer stem cells in head and neck squamous cell carcinoma. Arch
Otolaryngol Head Neck Surg. 136:1260–1266. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Arnold CR, Mangesius J, Skvortsova II and
Ganswindt U: The role of cancer stem cells in radiation resistance.
Front Oncol. 10(164)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Szumiel I: Ionizing radiation-induced
oxidative stress, epigenetic changes and genomic instability: The
pivotal role of mitochondria. Int J Radiat Biol. 91:1–12.
2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xia P and Xu XY: PI3K/Akt/mTOR signaling
pathway in cancer stem cells: From basic research to clinical
application. Am J Cancer Res. 5:1602–1609. 2015.PubMed/NCBI
|
|
25
|
Ohuchi K, Saga R, Hasegawa K, Tsuruga E,
Hosokawa Y, Fukumoto M and Okumura K: DNA-PKcs phosphorylation
specific inhibitor NU7441 enhances the radiosensitivity of
clinically relevant radioresistant oral squamous cell carcinoma
cells. Biomed Rep. 18(28)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dewangan J, Srivastava S and Rath SK:
Salinomycin: A new paradigm in cancer therapy. Tumour Biol.
39(1010428317695035)2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kim KY, Park KI, Kim SH, Yu SN, Lee D, Kim
YW, Noh KT, Ma JY, Seo YK and Ahn SC: Salinomycin induces reactive
oxygen species and apoptosis in aggressive breast cancer cells as
mediated with regulation of autophagy. Anticancer Res.
37:1747–1758. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tyagi M and Patro BS: Salinomycin reduces
growth, proliferation and metastasis of cisplatin resistant breast
cancer cells via NF-κB deregulation. Toxicol In Vitro. 60:125–131.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Patel S, Patel A, Nair A, Shah K, Shah K,
Tanavde V and Rawal R: Salinomycin mediated therapeutic targeting
of circulating stem like cell population in oral cancer. J Biomol
Struct Dyn. 40:11141–11153. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lim YC, Ensbey KS, Offenhäuser C, D'souza
RCJ, Cullen JK, Stringer BW, Quek H, Bruce ZC, Kijas A, Cianfanelli
V, et al: Simultaneous targeting of DNA replication and homologous
recombination in glioblastoma with a polyether ionophore. Neuro
Oncol. 22:216–228. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang Y, Zuo Y, Guan Z, Lu W, Xu Z, Zhang
H, Yang Y, Yang M, Zhu H and Chen X: Salinomycin radiosensitizes
human nasopharyngeal carcinoma cell line CNE-2 to radiation. Tumour
Biol. 37:305–311. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tomita K, Fukumoto M, Itoh K, Kuwahara Y,
Igarashi K, Nagasawa T, Suzuki M, Kurimasa A and Sato T: MiR-7-5p
is a key factor that controls radioresistance via intracellular
Fe2+ content in clinically relevant radioresistant cells. Biochem
Biophys Res Commun. 518:712–718. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mai TT, Hamaï A, Hienzsch A, Cañeque T,
Müller S, Wicinski J, Cabaud O, Leroy C, David A, Acevedo V, et al:
Salinomycin kills cancer stem cells by sequestering iron in
lysosomes. Nat Chem. 9:1025–1033. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhang G, Wang W, Yao C, Ren J, Zhang S and
Han M: Salinomycin overcomes radioresistance in nasopharyngeal
carcinoma cells by inhibiting Nrf2 level and promoting ROS
generation. Biomed Pharmacother. 91:147–154. 2017.PubMed/NCBI View Article : Google Scholar
|
